Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/20.500.12008/54650
Cómo citar
| Título: | SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis |
| Autor: | Efe, Cumali Taşçılar, Koray Gerussi, Alessio Bolis, Francesca Lammert, Craig Ebik, Berat Stättermayer, Albert F. Cengiz, Mustafa Gökçe, Dilara Turan Hernández, Nelia |
| Tipo: | Artículo |
| Palabras clave: | Autoimmunity, Breakthrough infection, Immunosuppression, Liver failure, Vaccine |
| Descriptores: | COVID-19, VACUNAS CONTRA LA COVID-19, AUTOINMUNIDAD, RIESGO A LA SALUD, ADULTOS, ADOLESCENTE, PERSONA DE MEDIANA EDAD, ANCIANO, HEPATITIS AUTOINMUNE, VACUNA BNT162, PRUEBA DE COVID-19, PREVENCIÓN DE ENFERMEDADES, HUMANOS, ESTUDIOS RETROSPECTIVOS, SARS-CoV-2, EPIDEMIOLOGÍA, VACUNACIÓN |
| Fecha de publicación: | 2022 |
| Resumen: | Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH. |
| Descripción: | Cumali Efe a,∗,1, Koray Taşçılar b,1, Alessio Gerussi c,d, Francesca Bolis c, Craig Lammert e, Berat Ebik f, Albert Friedrich Stättermayer g, Mustafa Cengiz h, Dilara Turan Gökçe i, Laura Cristoferi c,d, Mirta Peralta j,k, Hatef Massoumi l, Pedro Montes m, Eira Cerda n, Cristina Rigamonti o,p, Suna Yapalı q, Gupse Adali r, Ali Rıza Çalışkan s, Yasemin Balaban t, Fatih Eren u, Tuğçe Eşkazan v, Sezgin Barutçu w, Ellina Lytvyak x, Godolfino Miranda Zazueta y, Meral Akdogan Kayhan h, Alexandra Heurgue-Berlot z, Eleonora De Martin aa, Ahmet Yavuz ab, Murat Bıyık ab, Graciela Castro Narro y, Serkan Duman ac, Nelia Hernandez ad, Nikolaos K Gatselis ae,af, Jonathan Aguirre ag, Ramazan Idilman ac, Marcelo Silva k,ah, Manuel Mendizabal k,ah, Kadri Atay ai, Fatih Güzelbulut aj, Renumathy Dhanasekaran ak, Aldo J Montano-Loza x, George N Dalekos ae,af,2, Ezequiel Ridruejo k,ah,al,2, Pietro Invernizzi c,d,2, Staffan Wahlin am,2 aDepartment of Gastroenterology, Harran University Hospital, Şanlıurfa, Turkey bDepartment of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany cDivision of Gastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy dEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy eDepartment of Medicine Indiana, University School of Medicine, Indianapolis, IN, USA fDepartment of Gastroenterology, Gazi Yaşargil Education and Research Hospital, Diyarbakir, Turkey gDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria hDepartment of Gastroenterology, Gülhane Training and Research Hospital, Ankara, Turkey iDepartment of Gastroenterology, Ankara City Hospital, Ankara, Turkey jHepatology Section, Hospital Francisco J Muñiz, Ciudad Autónoma de Buenos Aires, Argentina kLatin American Liver Research Educational and Awareness Network (LALREAN), Pilar, Argentina lDepartment of Medicine, Montefiore Medical Center, Bronx, NY, USA mGastroenterology and Hepatology Unit, Hospital Nacional Daniel A. Carrión, Callao, Peru nHepatology Unit, Hospital Militar Central de México, Ciudad de México, Mexico oDepartment of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy pDivision of Internal Medicine, “AOU Maggiore della Carità”, Novara, Italy qDepartment of Gastroenterology, Acıbadem University School of Medicine, İstanbul, Turkey rDepartment of Gastroenterology, Umraniye Education and Research Hospital, Istanbul, Turkey sDepartment of Gastroenterology, Adıyaman University, Adıyaman, Turkey tDepartment of Gastroenterology, Faculty of Medicine, Hacettepe University, Ankara, Turkey uDepartment of Gastroenterology, Medical Faculty, Uludag University, Bursa, Turkey vDepartment of Gastroenterology, Cerrahpaşa School of Medicine, İstanbul, Turkey wDepartment of Gastroenterology, University of Gaziantep Medical Faculty, Gaziantep, Turkey xUniversity of Alberta Division of Gastroenterology and Liver Unit, Edmonton, AB, Canada yGastroenterology Unit, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Ciudad de México, Mexico zDepartment of Hepato-Gastroenterology, CHU Reims, Reims, France aaCentre Hepato-Biliaire, Hôpital Paul-Brousse, FHU Hepatinov, INSERM Unit UMR 1193, Univ Paris-Saclay, France abDivision of Gastroenterology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey acDepartment of Gastroenterology, Ankara University Medical Faculty, Ankara, Turkey adGastroenterology and Hepatology Unit, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay aeDepartment of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Greece afEuropean Reference Network on Hepatological Diseases (ERN RARE-LIVER), General University Hospital of Larissa, Larissa, Greece agHepatology Unit, Hospital Ángeles Pedregal, Ciudad de México, Mexico ahHepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Argentina aiDepartment of Gastroenterology, Mardin State Hospital, Mardin, Turkey ajDepartment of Gastroenterology, Haydarpaşa Numune Education and Research Hospital, İstanbul, Turkey akDivision of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA alHepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Ciudad Autónoma de Buenos Aires, Argentina amHepatology Division, Department of Upper GI Diseases, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden |
| Editorial: | Elsevier |
| EN: | Journal of Autoimmunity. 2022;132 |
| Citación: | Efe C, Taşçılar K, Gerussi A y otros. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. Journal of Autoimmunity [en línea]. 2022;132. 6 p. |
| Licencia: | Licencia Creative Commons Atribución (CC - By 4.0) |
| Aparece en las colecciones: | Publicaciones Académicas y Científicas - Facultad de Medicina |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | ||
|---|---|---|---|---|---|
| SARS CoV2 vaccination and risk of severe COVID19 outcomes.pdf | SARS CoV2 vaccination and risk of severe COVID19 outcomes | 619,94 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons
